Raymond James & Associates’s Harmony Biosciences HRMY Stock Holding History

Raymond James & Associates’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,594	Closed	-$216K	–	3877
2023 Q3	$216K	Buy	+6,594	New	+$229K	﹤0.01%	3418
2022 Q3	–	Sell	-6,932	Closed	-$338K	–	4033
2022 Q2	$338K	Buy	+6,932	New	+$312K	﹤0.01%	3154

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Raymond James & Associates's HRMY Position: Q4 2023 in Review

Raymond James & Associates sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 6,594 shares — an estimated $216K sold.

Raymond James & Associates first reported a position in HRMY in Q2 2022 and held it in 2 quarters. The position peaked at $338K in Q2 2022. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

Raymond James & Associates reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
Raymond James & Associates sold 6,594 Harmony Biosciences shares in Q4 2023, an estimated $216K.
Raymond James & Associates first reported a position in Harmony Biosciences in Q2 2022 and held it in 2 quarters.
Raymond James & Associates's Harmony Biosciences position peaked at $338K in Q2 2022.
221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.